Mitochondrial‐Derived Peptide MOTS‐c Suppresses Ovarian Cancer Progression by Attenuating USP7‐Mediated LARS1 Deubiquitination
Advanced Science · 2024
DOI: 10.1002/advs.202405620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yadong Yin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology and Obstetrics, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Ubiquitin-Specific Peptidase 7, Ubiquitination, Disease Progression. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shaanxi Provincial Natural Science Basic Research Program, Shaanxi Provincial Innovation Platform.
Abstract (Originalsprache)
Mitochondrial‐nuclear communication plays a vital role in maintaining cellular homeostasis. MOTS‐c, a short peptide derived from the 12S rRNA of mitochondrial DNA, has been suggested as a retrograde mitochondrial signal. Although recent clinical studies have suggested a possible link between MOTS‐c and human cancer, the role of MOTS‐c in tumorigenesis has yet to be investigated. Here, MOTS‐c levels are found to be reduced in both serum and tumor tissues from ovarian cancer (OC) patients, which are associated with poor patients’ prognosis. Exogenous MOTS‐c inhibits the proliferation, migration and invasion of OC cells, and induces cell cycle arrest and apoptosis. Mechanistically, MOTS‐c interacts with LARS1 and promotes its ubiquitination and proteasomal degradation. In addition, USP7 was identified as a deubiquitinase of LARS1, and MOTS‐c can attenuates USP7‐mediated LARS1 deubiquitination by competing with USP7 for binding to LARS1. Besides, LARS1 was found to be increased and play an important oncogenic function in OC. More importantly, MOTS‐c displays a marked anti‐tumor effect on OC growth without systemic toxicity in vivo. In conclusion, this study reveals a crucial role of MOTS‐c in OC and provides a possibility for MOTS‐c as a therapeutic target for the treatment of this manlignacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecology and Obstetrics, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
- Department of Traditional Chinese Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Physiology and Pathophysiology, Air Force Medical University, Xi'an, 710032, China.
ORCID-Profile: Hong Yang
Förderung
- National Natural Science Foundation of China
- Shaanxi Provincial Natural Science Basic Research Program
- Shaanxi Provincial Innovation Platform
- Shaanxi Provincial Key Industry Innovation Chain
Zitieren
APA
Yin, Y., Li, Y., Ma, B., Ren, C., Zhao, S., Li, J., Gong, Y., Yang, H., & Li, J. (2024). Mitochondrial‐Derived Peptide MOTS‐c Suppresses Ovarian Cancer Progression by Attenuating USP7‐Mediated LARS1 Deubiquitination. Advanced Science. https://doi.org/10.1002/advs.202405620
Vancouver
Yin Y, Li Y, Ma B, Ren C, Zhao S, Li J, et al. Mitochondrial‐Derived Peptide MOTS‐c Suppresses Ovarian Cancer Progression by Attenuating USP7‐Mediated LARS1 Deubiquitination. Advanced Science. 2024. doi:10.1002/advs.202405620
BibTeX
@article{Yin2024,
author = {Yin, Yadong and Li, Yujie and Ma, Boyi and Ren, Chenlu and Zhao, Shuhua and Li, Jia and Gong, Yun and Yang, Hong and Li, Jibin},
title = {Mitochondrial‐Derived Peptide MOTS‐c Suppresses Ovarian Cancer Progression by Attenuating USP7‐Mediated LARS1 Deubiquitination},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202405620}
}
EUVIMED